아시아 태평양 비호지킨 림프종 진단 시장 – 2030년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Medical Devices Asia Pacific Non Hodgkin Lymphoma Diagnostics Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 비호지킨 림프종 진단 시장 – 2030년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Apr 2023
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 517
  • 그림 수: 52
지금 구매 지금 구매

Asia Pacific Non Hodgkin Lymphoma Diagnostics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2030
Diagram 시장 규모(기준 연도)
 백만 달러
요구
Diagram 시장 규모(예측 연도)
 백만 달러
잠금 해제 요청
Diagram 연평균 성장률
 %
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
잠금 해제 요청

>아시아 태평양 비호지킨 림프종 진단 시장, 검사 유형(영상, 생검, 면역조직화학, 바이오마커, 유전자 검사 , 세포유전학, 요추 천자, 혈액 검사, 세포화학 및 기타), 암 병기(4기, 3기, 2기, 1기 및 0기), 종양 유형(공격적 림프종 및 무증상 림프종), 제품(기기 기반 제품, 플랫폼 기반 제품, 키트 및 시약 및 기타 소모품), 기술(형광 현장 교잡법, 차세대 시퀀싱, 형광면역 검정법, 비교 유전체 교잡법, 면역조직화학 및 기타), 응용 분야(선별, 진단 및 예측, 예후 및 연구), 최종 사용자(병원, 진단 센터, 암 연구 센터, 학술 기관, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2030년 예측.

아시아 태평양 비호지킨 림프종 진단 시장

아시아 태평양 비호지킨 림프종 진단 시장 분석 및 통찰력

아시아 태평양 지역에서 비호지킨 림프종에 대한 인식이 증가함에 따라 시장 수요가 증가했습니다. 더 나은 건강 서비스를 위한 의료비 지출 증가도 시장 성장에 기여합니다. 주요 시장 참여자들은 이 중요한 기간 동안 다양한 서비스 출시와 승인에 집중합니다. 또한, 개선된 진단 프로세스와 기술의 증가도 비호지킨 림프종 진단 검사에 대한 수요 증가에 기여합니다.

아시아 태평양 비호지킨 림프종 진단 시장아시아 태평양 비호지킨 림프종 진단 시장

아시아 태평양 비호지킨 림프종 진단 시장은 시장 참여자의 증가와 고급 서비스의 가용성으로 인해 예측 연도에 성장할 것으로 예상됩니다. 이와 함께 제조업체는 시장에서 새로운 서비스를 출시하기 위한 R&D 활동에 참여하고 있습니다. 비호지킨 림프종 진단 및 개발 분야의 연구가 증가함에 따라 시장 성장이 더욱 촉진되고 있습니다. 그러나 비호지킨 림프종 스크리닝 기술의 어려움은 예측 기간 동안 아시아 태평양 비호지킨 림프종 진단 시장의 성장을 방해할 수 있습니다.

암 진단 및 치료에 대한 의료비 지출 증가는 시장에 치료를 개선할 기회를 제공할 것으로 예상됩니다. 그러나 높은 테스트 비용과 암 진단 제품의 승인 및 상용화에 대한 엄격한 규정 및 표준은 시장 성장에 도전이 될 수 있습니다.

아시아 태평양 비호지킨 림프종 진단 시장은 긍정적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 아시아 태평양 비호지킨 림프종 진단 시장이 2023년에서 2030년까지의 예측 기간 동안 8.4%의 CAGR로 성장할 것이라고 분석합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020까지 사용자 정의 가능)

양적 단위

매출은 백만 달러이고 가격은 미화입니다.

다루는 세그먼트

테스트 유형(영상, 생검, 면역조직화학, 바이오마커, 유전자 검사, 세포유전학, 요추 천자, 혈액 검사, 세포화학 및 기타), 암 병기(4기, 3기, 2기, 1기 및 0기), 종양 유형(공격적 림프종 및 무증상 림프종), 제품(기기 기반 제품, 플랫폼 기반 제품, 키트 및 시약 및 기타 소모품), 기술(형광 현장 교잡법 , 차세대 시퀀싱, 형광면역측정법, 비교 유전체 교잡법, 면역조직화학 및 기타), 응용 분야(선별, 진단 및 예측, 예후 및 연구), 최종 사용자(병원, 진단 센터, 암 연구 센터, 학술 기관, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타)

적용 국가

중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 기타 아시아 태평양 지역

시장 참여자 포함

CANON MEDICAL SYSTEMS CORPORATION(일본 도치기현), Koninklijke Philips NV(네덜란드 암스테르담), Siemens Healthcare GmbH(독일 에를랑겐), Danaher(미국 워싱턴), Bio-Rad Laboratories, Inc(미국 캘리포니아), General Electric Company(미국 매사추세츠), Sysmex Corporation(일본 효고), Grail(미국 캘리포니아), F. Hoffmann-La Roche(스위스 바젤), Neusoft Corporation(중국 선양), Agilent Technologies, Inc.(미국 캘리포니아), NeoGenomics Laboratories(미국 플로리다), Hologic, Inc(미국 매사추세츠), Integrated DNA Technologies, Inc., CENTOGENE NV(독일 로스토크), Merit Medical Systems(미국 유타), Invitae Corporation(미국 캘리포니아), PerkinElmer Inc.(미국 매사추세츠), QIAGEN(캘리포니아, 미국), GeneDx, LLC(코네티컷, 미국) 등이 있습니다.

 

시장 정의

암은 림프에서 시작되며 대부분 흡연자에게 발생합니다. 비호지킨 림프종의 두 가지 주요 유형은 공격적 비호지킨 림프종과 무증상 비호지킨 림프종입니다. 비호지킨 림프종의 원인에는 흡연, 간접 흡연, 특정 독소에 노출, 가족력이 있습니다.

증상에는 기침(종종 피가 섞임), 흉통, 천명음, 체중 감소가 있습니다. 이러한 증상은 종종 암이 진행될 때까지 나타나지 않습니다. 치료법은 다양하지만 수술, 화학 요법, 방사선 요법, 표적 약물 요법, 면역 요법을 포함할 수 있습니다.

아시아 태평양 비호지킨 림프종 진단 시장 역학

이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래와 같이 자세히 논의됩니다.

  • 비호지킨 림프종 유병률 증가

림프종은 "림프구"라고 불리는 백혈구의 일종에서 발생하는 많은 관련 하위 유형의 암에 대한 일반적인 명칭입니다. 림프종은 호지킨 림프종(HL)과 비호지킨 림프종(NHL)의 두 가지 주요 범주로 나뉩니다. 비호지킨 림프종은 림프종의 일반적인 범주입니다. 이 범주에 속하는 하위 유형이 많이 있습니다. 확산성 대형 B 세포 림프종과 모낭 림프종이 가장 흔한 하위 유형 중 하나입니다. 림프종 암 사례는 전 세계적으로 증가하고 있습니다. 비호지킨 림프종(NHL)은 미국에서 가장 흔한 암 중 하나로 모든 암의 약 4%를 차지합니다.

남성이 평생 동안 NHL을 발병할 확률은 약 1/43이고, 여성의 경우 위험은 약 1/53입니다. 세계보건기구(WHO)의 국제암연구소에 따르면 2020년 전 세계적으로 비호지킨 림프종 진단을 받은 사람은 약 544,352명으로 추산됩니다.

  • 비호지킨 림프종에 대한 인식 증가

비호지킨 림프종 인식은 이러한 질병에 대한 지식을 높이고 원인, 예방, 진단, 치료 및 생존에 대한 연구를 조명할 수 있는 기회입니다. 목표는 림프종의 영향을 받은 사람들을 돕고 건강한 습관을 장려하는 것입니다.

세계에서 다섯 번째로 흔한 암은 림프종입니다. 세계보건기구의 보고서에 따르면 아시아는 지난 5년간 241,270명의 환자로 가장 높은 발병률을 보였습니다. 또한 비호지킨 림프종은 아시아에서 모든 암 사망자의 7.4%를 차지합니다. 사망률은 매년 매우 느리게 증가했습니다.

매년 전 세계적으로 비호지킨 림프종에 대한 교육을 위해 여러 인식 캠페인, 웨비나 및 컨퍼런스가 계획되고 있으며, 다양한 조직이 이러한 캠페인을 주도하고 있습니다. 결과적으로 이는 아시아 태평양 비호지킨 림프종 진단 시장의 성장을 촉진할 것으로 예상됩니다.

  • 훈련되고 숙련된 의료 전문가의 가용성 부족

전체 건강 인력의 밀도는 10,000명당 29명으로 추산되지만, 훈련된 근로자의 경우 10,000명당 16명에 불과합니다. 숙련되고 인증된 전문가에 대한 요구는 아시아 태평양 비호지킨 림프종 진단 시장에 큰 제약이 됩니다. 암 질환과 유전적 이상 사례가 증가함에 따라 형광 현장 하이브리다이제이션에 대한 수요가 증가하지만, 숙련된 전문가의 수가 줄어들어 시장 성장이 방해받을 것으로 예상됩니다.

자격을 갖춘 의료 종사자가 수많은 검사를 실시할 수 있는 능력은 의료 및 의료 분야의 성장에 매우 중요합니다. 전문가 팀을 갖는 주요 목표는 생명을 구하는 모든 의료 장비가 가장 필요할 때 효과적으로 작동하도록 보장하는 것입니다. 기술자는 관련 제조업체 및 당국에서 적절한 교육과 인증을 받아야 합니다.

기술자들은 효율적으로 절차를 수행하기 위해 고급 방법을 안전하게 적용하는 문제와 관련된 기술 교육 격차에 직면합니다. 림프종 진단을 위해 방법 개발, 검증, 운영 및 문제 해결 활동을 위한 숙련된 전문가에 대한 수요가 높습니다.

  • 다양한 치료 및 진단에 대한 엄격한 규정 및 지침

이러한 관할권에서 의료 기기나 약물을 판매하는 데는 상당한 재정적 지출이 수반될 수 있으며, 완료하는 데 몇 달 또는 몇 년이 걸릴 수 있습니다. 이러한 제약 조건을 이해하거나 고려하지 않으면 지연으로 인해 경쟁이 치열한 시장에서 성공 가능성이 심각하게 위태로워질 수 있습니다. 그러나 전 세계 여러 지역에서 승인 및 마케팅하려면 엄격한 규제 표준을 충족하고 다양한 규제 기관의 승인을 받아야 합니다.

회사는 식품의약국(FDA) 프로토콜에 따라 분류하기 전에 제품 사양을 신중하게 검토해야 합니다. 학계, 비영리 및 기타 생명 과학 연구 회사에서 약물 발견 및 개발 프로그램을 설정하려면 신중한 계획이 필요합니다. 모든 국가에는 자체 규제 기관이 있으며 규제 기관은 약물 발견 연구에 대한 최소한의 감독을 하지만 이 과정에서 이정표를 달성하기 위한 특정 요구 사항과 명확한 문서를 제공합니다. 규제 프레임워크는 더 나은 품질을 위한 접근성을 개선하고 규제 통제 강화에 대한 지침을 제공하는 것을 목표로 합니다. 

아시아 태평양 비호지킨 림프종 진단 시장에 대한 COVID-19 이후의 영향

전 세계 의료 시스템에 대한 COVID-19의 높은 부담은 의학 종양학자들 사이에서 COVID-19가 비호지킨 림프종 진단 및 치료에 미치는 영향에 대한 우려를 불러일으켰습니다. 이 회고적 코호트 연구에서 우리는 COVID-19가 COVID-19 시대 전후의 비호지킨 림프종 진단 및 치료에 미치는 영향을 조사했습니다. 팬데믹 동안 새로운 비호지킨 림프종 진단은 질병의 단계가 약간 더 진행됨에 따라 감소했으며, 첫 번째 확정적 치료로서 방사선 수술이 상당히 증가했고 전신적 치료와 수술은 COVID-19 이전 시대와 비교하여 감소했습니다. COVID-19 이전 시대와 비교했을 때, 팬데믹 동안 화학 요법과 방사선 치료를 시작하는 데 상당한 지연은 없었습니다.

그러나 팬데믹 동안 우리는 비호지킨 림프종 수술이 지연되는 것을 관찰했습니다. COVID-19는 비호지킨 림프종 센터에서 비호지킨 림프종 환자의 진단 및 치료 패턴에 상당한 영향을 미친 것으로 보입니다. 많은 종양학자는 내년에 새로 진단된 비호지킨 림프종 환자의 수가 증가할 것을 우려하고 있습니다. 이 연구는 아직 진행 중이며, COVID-19 팬데믹이 비호지킨 림프종 환자 집단에 미치는 전반적인 영향을 더 잘 이해하기 위해 더 많은 정보를 수집하고 분석할 것입니다.

최근 개발

  • 2022년 11월, Danaher는 Duke University와 전략적 파트너십을 맺어 첫 번째 Danaher Beacon for Gene Therapy Innovation을 구성했다고 발표했습니다. 이 프로그램은 게놈 의학, 정밀 진단, 차세대 바이오 제조, 인간 시스템 및 데이터 과학에 중점을 두고 외부 R&D 전략을 발전시키기 위한 제품 혁신에 투자합니다.
  • 2022년 8월, Bio-Rad Laboratories Inc.는 의료 진단 및 헬스케어 시장을 위한 혁신적 기술 솔루션을 개발하는 폴란드 기반 회사인 Curiosity Diagnostics를 인수했습니다. 이를 통해 회사는 제품 포트폴리오와 아시아 태평양 시장에서의 입지를 확대할 수 있었습니다.

아시아 태평양 비호지킨 림프종 진단 시장 세분화

아시아 태평양 비호지킨 림프종 진단 시장은 테스트 유형, 암 단계, 종양 유형, 제품, 기술, 응용 프로그램, 최종 사용자 및 유통 채널을 기준으로 8개의 주요 세그먼트로 분류됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

테스트 유형별

  • 이미징
  •  생검
  •  면역조직화학
  •  바이오마커 테스트
  •  유전자 검사
  •  세포유전학
  •  요추 천자(척추 천자)
  •  혈액 검사
  •  세포화학
  •  기타

암 병기별

  • 0단계
  • 1단계
  • 2단계
  • 3단계
  • 4단계

종양 유형별

  • 공격적 림프종
  • 무증상 림프종

제품별

  • 계측 기반 제품
  • 플랫폼 기반 제품
  • 키트 및 시약
  • 기타 소모품

기술에 의해

  • 형광 현장 하이브리디제이션
  • 차세대 시퀀싱
  • 형광면역측정법
  • 비교 게놈 교잡화
  • 면역조직화학
  • 기타

응용 프로그램별

  • 상영
  • 진단 및 예측
  • 전조
  • 연구

최종 사용자별

  • 병원
  • 진단 센터
  • 암 연구 센터
  • 학술 기관
  • 외래 수술 센터
  • 기타

유통 채널별

  • 직접 입찰
  • 소매 판매
  • 기타

비호지킨 림프종 진단 시장

아시아 태평양 비호지킨 림프종 진단 시장 지역 분석/통찰력

아시아 태평양 비호지킨 림프종 진단 시장을 분석하고, 위에 언급된 대로 시험 유형, 암 단계, 종양 유형, 제품, 기술, 응용 분야, 최종 사용자, 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

비호지킨 림프종 진단 보고서에서 다루는 국가는 중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 기타 아시아 태평양 지역입니다.   

중국은 아시아 태평양 비호지킨 림프종 진단 시장을 지배하고 있습니다. 비호지킨 림프종 진단 및 개발 분야의 연구가 증가함에 따라 시장 성장이 더욱 촉진되고 있습니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 하류 및 상류 가치 사슬 분석, 기술 추세, 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 아시아 태평양 비호지킨 림프종 진단 시장 점유율 분석

아시아 태평양 비호지킨 림프종 진단 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 시설 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 아시아 태평양 비호지킨 림프종 진단 시장에 대한 회사의 초점과만 관련이 있습니다.

이 시장에서 활동하는 주요 기업으로는 CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips NV, Siemens Healthcare GmbH, Danaher., Bio-Rad Laboratories, Inc., General Electric Company, Sysmex Corporation, Grail, F. Hoffmann-La Roche, Neusoft Corporation, Agilent Technologies, Inc., NeoGenomics Laboratories, Hologic, Inc, Integrated DNA Technologies, Inc., CENTOGENE NV, Merit Medical Systems, Invitae Corporation, PerkinElmer Inc., QIAGEN, GeneDx, LLC 등이 있습니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

5 INDUSTRY INSIGHTS

6 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA

7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA

7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA

7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP

 

7.2 RESTRAINTS

7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS

7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS

7.3 OPPORTUNITIES

7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS

7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D

7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS

7.4 CHALLENGES

7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE

7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT

7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL)

8 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING

8.2.1 COMPUTED TOMOGRAPHY (CT)

8.2.2 CHEST X-RAY

8.2.3 MAGNETIC RESONANCE IMAGING (MRI)

8.2.4 ULTRASOUND

8.2.5 POSITRON EMISSION TOMOGRAPHY (PET)

8.3 BIOPSY

8.3.1 EXCISIONAL OR INCISIONAL BIOPSY

8.3.2 CORE NEEDLE BIOPSY

8.4 IMMUNOHISTOCHEMISTRY

8.5 BIOMARKER TEST

8.5.1 BETA 2-M

8.5.2 LDH

8.5.3 CA-125

8.5.4 TP53

8.5.5 NPM1

8.5.6 OTHERS

8.6 GENETIC TEST

8.7 CYTOGENETICS

8.8 LUMBAR PUNCTURE (SPINAL TAP)

8.9 BLOOD TEST

8.1 CYTOCHEMISTRY

8.11 OTHERS

 

9 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE

9.1 OVERVIEW

9.2 AGGRESSIVE LYMPHOMAS

9.2.1 DIFFUSE LARGE B CELL LYMPHOMA

9.2.1.1 INSTRUMENT BASED PRODUCTS

9.2.1.2 PLATFORM BASED PRODUCTS

9.2.1.3 KITS AND REAGENTS

9.2.1.4 OTHER CONSUMABLES

9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA

9.2.2.1 INSTRUMENT BASED PRODUCTS

9.2.2.2 PLATFORM BASED PRODUCTS

9.2.2.3 KITS AND REAGENTS

9.2.2.4 OTHER CONSUMABLES

9.2.3 MANTLE CELL LYMPHOMA

9.2.3.1 INSTRUMENT BASED PRODUCTS

9.2.3.2 PLATFORM BASED PRODUCTS

9.2.3.3 KITS AND REAGENTS

9.2.3.4 OTHER CONSUMABLES

9.2.4 PERIPHERAL T-CELL LYMPHOMA

9.2.4.1 INSTRUMENT BASED PRODUCTS

9.2.4.2 PLATFORM BASED PRODUCTS

9.2.4.3 KITS AND REAGENTS

9.2.4.4 OTHER CONSUMABLES

9.2.5 LYMPHOBLASTIC LYMPHOMA

9.2.5.1 INSTRUMENT BASED PRODUCTS

9.2.5.2 PLATFORM BASED PRODUCTS

9.2.5.3 KITS AND REAGENTS

9.2.5.4 OTHER CONSUMABLES

9.2.6 BURKITT LYMPHOMA

9.2.6.1 INSTRUMENT BASED PRODUCTS

9.2.6.2 PLATFORM BASED PRODUCTS

9.2.6.3 KITS AND REAGENTS

9.2.6.4 OTHER CONSUMABLES

 

9.3 INDOLENT LYMPHOMAS

9.3.1 FOLLICULAR LYMPHOMA

9.3.1.1 INSTRUMENT BASED PRODUCTS

9.3.1.2 PLATFORM BASED PRODUCTS

9.3.1.3 KITS AND REAGENTS

9.3.1.4 OTHER CONSUMABLES

9.3.2 CUTANEOUS T-CELL LYMPHOMA

9.3.2.1 INSTRUMENT BASED PRODUCTS

9.3.2.2 PLATFORM BASED PRODUCTS

9.3.2.3 KITS AND REAGENTS

9.3.2.4 OTHER CONSUMABLES

9.3.3 MARGINAL ZONE B CELL LYMPHOMA

9.3.3.1 INSTRUMENT BASED PRODUCTS

9.3.3.2 PLATFORM BASED PRODUCTS

9.3.3.3 KITS AND REAGENTS

9.3.3.4 OTHER CONSUMABLES

9.3.4 LYMPHOPLASMACYTIC LYMPHOMA

9.3.4.1 INSTRUMENT BASED PRODUCTS

9.3.4.2 PLATFORM BASED PRODUCTS

9.3.4.3 KITS AND REAGENTS

9.3.4.4 OTHER CONSUMABLES

9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA

9.3.5.1 INSTRUMENT BASED PRODUCTS

9.3.5.2 PLATFORM BASED PRODUCTS

9.3.5.3 KITS AND REAGENTS

9.3.5.4 OTHER CONSUMABLES

10 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 SCREENING

10.2.1 INSTRUMENT BASED PRODUCTS

10.2.2 PLATFORM BASED PRODUCTS

10.2.3 KITS AND REAGENTS

10.2.4 OTHER CONSUMABLES

10.3 DIAGNOSTIC AND PREDICTIVE

10.3.1 INSTRUMENT BASED PRODUCTS

10.3.2 PLATFORM BASED PRODUCTS

10.3.3 KITS AND REAGENTS

10.3.4 OTHER CONSUMABLES

10.4 PROGNOSTIC

10.4.1 INSTRUMENT BASED PRODUCTS

10.4.2 PLATFORM BASED PRODUCTS

10.4.3 KITS AND REAGENTS

10.4.4 OTHER CONSUMABLES

10.5 RESEARCH

10.5.1 INSTRUMENT BASED PRODUCTS

10.5.2 PLATFORM BASED PRODUCTS

10.5.3 KITS AND REAGENTS

10.5.4 OTHER CONSUMABLES

11 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE

11.1 OVERVIEW

11.2 STAGE IV

11.3 STAGE I

11.4 STAGE III

11.5 STAGE II

11.6 STAGE 0

12 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY

12.1 OVERVIEW

12.2 FLUORESCENT IN SITU HYBRIDIZATION

12.3 NEXT GENERATION SEQUENCING

12.4 FLUORIMMUNOASSAY

12.5 COMPARATIVE GENOMIC HYBRIDIZATION

12.6 IMMUNOHISTOLOCHEMICAL

12.7 OTHER

13 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT

13.1 OVERVIEW

13.2 INSTRUMENT BASED PRODUCTS

13.2.1 IMAGING

13.2.2 BIOPSY

13.3 PLATFORM BASED PRODUCTS

13.3.1 NEXT-GENERATION SEQUENCING

13.3.2 MICROARRAYS

13.3.3 PCR

13.3.4 OTHERS

13.4 KITS AND REAGENTS

13.4.1 NON-HODGKIN LYMPHOMA PANELS

13.4.2 IMMUNOHISTOCHEMISTRY STAINS

13.4.3 OTHERS

13.5 OTHER CONSUMABLES

14 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC CENTERS

14.4 CANCER RESEARCH CENTERS

14.5 ACADEMIC INSTITUTES

14.6 AMBULATORY SURGICAL CENTERS

14.7 OTHERS

15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

15.4 OTHERS

16 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 INDIA

16.1.4 AUSTRALIA

16.1.5 SOUTH KOREA

16.1.6 INDONESIA

16.1.7 PHILIPPINES

16.1.8 THAILAND

16.1.9 MALAYSIA

16.1.10 VIETNAM

16.1.11 SINGAPORE

16.1.12 REST OF ASIA-PACIFIC

17 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

 

18 SWOT ANALYSIS

19 ASIA PACIFIC NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET

19.1 CANON MEDICAL SYSTEMS CORPORATION

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 KONINKLIJKE PHILIPS N.V.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 SIEMENS HEALTHCARE GMBH

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 DANAHER.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 BIO-RAD LABORATORIES, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 AGILENT TECHNOLOGIES, INC.

19.6.1 COMPANY PROFILE

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

 

19.7 CENTOGENE N.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 F. HOFFMANN- LA ROCHE LTD

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 GENERAL ELECTRIC COMPANY

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 GENEDX, LLC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 GRAIL

19.11.1 COMPANY PROFILE

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 HOLOGIC INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 INVITAE CORPORATION

19.13.1 COMPANY PROFILE

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

19.14 NEUSOFT CORPORATION

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENT

 

19.15 NEOGENOMICS LABORATORIES

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

19.16 PERKINELMER INC

19.16.1 COMPANY PROFILE

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 QIAGEN

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 SYSMEX CORPORATION

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 36 ASIA PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA PACIFIC STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA PACIFIC STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION

TABLE 45 ASIA PACIFIC STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 47 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 ASIA PACIFIC NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 ASIA PACIFIC FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 ASIA PACIFIC IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 54 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 56 ASIA PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 ASIA PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 58 ASIA PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 60 ASIA PACIFIC OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))

TABLE 61 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 62 ASIA PACIFIC HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 ASIA PACIFIC DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 ASIA PACIFIC CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 ASIA PACIFIC ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 67 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 68 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 ASIA PACIFIC DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 70 ASIA PACIFIC RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 71 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 90 ASIA-PACIFIC LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 91 ASIA-PACIFIC SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 92 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 95 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 96 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 97 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 98 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 99 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 100 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 101 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 102 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 103 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 104 ASIA-PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 105 ASIA-PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 106 ASIA-PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 107 ASIA-PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 108 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 109 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 110 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 111 CHINA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 112 CHINA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 113 CHINA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 114 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 115 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 116 CHINA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 117 CHINA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 118 CHINA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 119 CHINA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 120 CHINA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 121 CHINA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 122 CHINA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 CHINA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 124 CHINA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 125 CHINA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 126 CHINA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 127 CHINA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 128 CHINA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 129 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 130 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 131 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 132 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 133 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 134 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 135 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 136 CHINA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 137 CHINA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 138 CHINA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 139 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 140 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 CHINA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 CHINA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 CHINA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 144 CHINA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 145 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 146 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 147 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 148 JAPAN IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 149 JAPAN BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 JAPAN BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 151 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 152 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 153 JAPAN AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 154 JAPAN DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 155 JAPAN ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 JAPAN MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 157 JAPAN PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 158 JAPAN LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 159 JAPAN BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 160 JAPAN INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 161 JAPAN FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 162 JAPAN CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 163 JAPAN MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 164 JAPAN LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 165 JAPAN SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 166 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 167 JAPAN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 168 JAPAN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 169 JAPAN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 170 JAPAN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 171 JAPAN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 172 JAPAN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 173 JAPAN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 174 JAPAN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 175 JAPAN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 176 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 177 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 178 JAPAN SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 179 JAPAN DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 180 JAPAN PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 JAPAN RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 183 JAPAN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 184 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 185 INDIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 INDIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 INDIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 188 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 189 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 190 INDIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 191 INDIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 192 INDIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 193 INDIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 194 INDIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 195 INDIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 196 INDIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 INDIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 198 INDIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 199 INDIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 200 INDIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 INDIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 202 INDIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 203 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 INDIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 205 INDIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 206 INDIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 207 INDIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 208 INDIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 209 INDIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 210 INDIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 INDIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 212 INDIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 213 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 214 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 215 INDIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 216 INDIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 217 INDIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 218 INDIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 219 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 220 INDIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 228 AUSTRALIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 229 AUSTRALIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 AUSTRALIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 231 AUSTRALIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 232 AUSTRALIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 AUSTRALIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 234 AUSTRALIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 235 AUSTRALIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 236 AUSTRALIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 237 AUSTRALIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 238 AUSTRALIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 AUSTRALIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 AUSTRALIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 242 AUSTRALIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 243 AUSTRALIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 244 AUSTRALIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 245 AUSTRALIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 246 AUSTRALIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 247 AUSTRALIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 248 AUSTRALIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 249 AUSTRALIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 250 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 251 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 252 AUSTRALIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 253 AUSTRALIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 254 AUSTRALIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 255 AUSTRALIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 256 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 257 AUSTRALIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 258 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 259 SOUTH KOREA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 260 SOUTH KOREA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 SOUTH KOREA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 262 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 263 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 264 SOUTH KOREA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 265 SOUTH KOREA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 266 SOUTH KOREA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 267 SOUTH KOREA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 SOUTH KOREA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 SOUTH KOREA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 270 SOUTH KOREA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 271 SOUTH KOREA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 272 SOUTH KOREA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 273 SOUTH KOREA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 274 SOUTH KOREA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 275 SOUTH KOREA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 276 SOUTH KOREA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 277 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 278 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 279 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 280 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 281 SOUTH KOREA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 282 SOUTH KOREA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 283 SOUTH KOREA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 284 SOUTH KOREA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 285 SOUTH KOREA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 286 SOUTH KOREA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 287 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 288 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 289 SOUTH KOREA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 290 SOUTH KOREA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 SOUTH KOREA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 292 SOUTH KOREA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 293 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 294 SOUTH KOREA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 295 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 296 INDONESIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 297 INDONESIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 298 INDONESIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 299 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 300 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 301 INDONESIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 302 INDONESIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 303 INDONESIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 304 INDONESIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 305 INDONESIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 306 INDONESIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 307 INDONESIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 308 INDONESIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 309 INDONESIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 310 INDONESIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 311 INDONESIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 312 INDONESIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 313 INDONESIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 314 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 315 INDONESIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 316 INDONESIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 317 INDONESIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 318 INDONESIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 319 INDONESIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 320 INDONESIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 321 INDONESIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 322 INDONESIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 323 INDONESIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 324 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 325 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 326 INDONESIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 327 INDONESIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 328 INDONESIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 329 INDONESIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 330 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 331 INDONESIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 332 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 333 PHILIPPINES IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 334 PHILIPPINES BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 335 PHILIPPINES BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 336 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 337 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 338 PHILIPPINES AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 339 PHILIPPINES DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 340 PHILIPPINES ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 341 PHILIPPINES MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 342 PHILIPPINES PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 343 PHILIPPINES LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 344 PHILIPPINES BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 345 PHILIPPINES INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 346 PHILIPPINES FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 347 PHILIPPINES CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 348 PHILIPPINES MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 349 PHILIPPINES LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 350 PHILIPPINES SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 351 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 352 PHILIPPINES INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 353 PHILIPPINES INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 354 PHILIPPINES INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 355 PHILIPPINES PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 356 PHILIPPINES PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 357 PHILIPPINES PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 358 PHILIPPINES KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 359 PHILIPPINES KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 360 PHILIPPINES KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 361 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 362 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 363 PHILIPPINES SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 364 PHILIPPINES DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 365 PHILIPPINES PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 366 PHILIPPINES RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 367 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 368 PHILIPPINES NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 369 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 THAILAND IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 371 THAILAND BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 372 THAILAND BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 373 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 374 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 375 THAILAND AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 376 THAILAND DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 377 THAILAND ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 378 THAILAND MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 379 THAILAND PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 380 THAILAND LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 381 THAILAND BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 382 THAILAND INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 383 THAILAND FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 384 THAILAND CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 385 THAILAND MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 386 THAILAND LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 387 THAILAND SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 388 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 389 THAILAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 390 THAILAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 391 THAILAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 392 THAILAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 393 THAILAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 394 THAILAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 395 THAILAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 396 THAILAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 397 THAILAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 398 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 399 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 400 THAILAND SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 401 THAILAND DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 402 THAILAND PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 403 THAILAND RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 404 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 405 THAILAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 406 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 407 MALAYSIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 408 MALAYSIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 409 MALAYSIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 410 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 411 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 412 MALAYSIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 413 MALAYSIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 414 MALAYSIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 415 MALAYSIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 416 MALAYSIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 417 MALAYSIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 418 MALAYSIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 419 MALAYSIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 420 MALAYSIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 421 MALAYSIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 422 MALAYSIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 423 MALAYSIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 424 MALAYSIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 425 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 426 MALAYSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 427 MALAYSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 428 MALAYSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 429 MALAYSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 430 MALAYSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 431 MALAYSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 432 MALAYSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 433 MALAYSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 434 MALAYSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 435 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 436 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 437 MALAYSIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 438 MALAYSIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 439 MALAYSIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 440 MALAYSIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 441 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 442 MALAYSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 443 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 444 VIETNAM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 445 VIETNAM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 446 VIETNAM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 447 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 448 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 449 VIETNAM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 450 VIETNAM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 451 VIETNAM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 452 VIETNAM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 453 VIETNAM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 454 VIETNAM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 455 VIETNAM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 456 VIETNAM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 457 VIETNAM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 458 VIETNAM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 459 VIETNAM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 460 VIETNAM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 461 VIETNAM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 462 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 463 VIETNAM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 464 VIETNAM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 465 VIETNAM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 466 VIETNAM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 467 VIETNAM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 468 VIETNAM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 469 VIETNAM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 470 VIETNAM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 471 VIETNAM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 472 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 473 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 474 VIETNAM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 475 VIETNAM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 476 VIETNAM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 477 VIETNAM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 478 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 479 VIETNAM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 480 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 481 SINGAPORE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 482 SINGAPORE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 483 SINGAPORE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 484 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 485 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 486 SINGAPORE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 487 SINGAPORE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 488 SINGAPORE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 489 SINGAPORE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 490 SINGAPORE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 491 SINGAPORE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 492 SINGAPORE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 493 SINGAPORE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 494 SINGAPORE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 495 SINGAPORE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 496 SINGAPORE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 497 SINGAPORE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 498 SINGAPORE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 499 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 500 SINGAPORE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 501 SINGAPORE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 502 SINGAPORE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 503 SINGAPORE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 504 SINGAPORE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 505 SINGAPORE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 506 SINGAPORE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 507 SINGAPORE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 508 SINGAPORE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 509 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 510 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 511 SINGAPORE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 512 SINGAPORE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 513 SINGAPORE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 514 SINGAPORE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 515 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 516 SINGAPORE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 517 REST OF ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET

FIGURE 15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 16 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 17 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 18 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 19 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022

FIGURE 20 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)

FIGURE 21 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030)

FIGURE 22 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE

FIGURE 23 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022

FIGURE 24 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 25 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 26 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022

FIGURE 28 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 29 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)

FIGURE 30 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE

FIGURE 31 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022

FIGURE 32 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 33 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 34 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 35 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022

FIGURE 36 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 37 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 38 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 39 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 40 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 41 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 45 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 48 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 49 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 52 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market is projected to grow at a CAGR of 8.4% during the forecast period by 2030.
The Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market is segmented on the basis of test type, cancer stage, tumor type, product, technology, application, end users, and distribution channel.
The major players in the Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market are CANON MEDICAL SYSTEMS CORPORATION (Tochigi Prefecture, Japan), Koninklijke Philips N.V.(Amsterdam, Netherland), Siemens Healthcare GmbH (Erlangen, Germany), Danaher (Washington U.S.), etc.
The countries covered in the Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.

관련 페이지 탐색

Banner